What are Iovance Biotherapeutics, Inc.'s profit margins?

Iovance Biotherapeutics, Inc. (IOVA) runs a 36.7% gross margin and a -127.2% operating margin, with a -123.9% net margin.

Where do Iovance Biotherapeutics, Inc.'s ratios come from?

Every ratio is computed from Iovance Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Iovance Biotherapeutics, Inc. IOVA Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Profitability
Gross margin	36.7%+5.4pp	31.3%+1.5pp	29.9%-0.3pp	30.2%-2.4pp	32.6%-1.6pp
Operating margin	-127.2%+25.9pp	-153.1%+13.2pp	-166.3%+3.7pp	-170%+17.5pp	-187.5%+53.4pp
Net margin	-123.9%+24.5pp	-148.4%+10.4pp	-158.8%+2.7pp	-161.4%+15.1pp	-176.5%+50.3pp
EBITDA margin	-122.6%+25.6pp	-148.3%+13.2pp	-161.4%+3.5pp	-164.9%+17.0pp	-181.9%+51.5pp
Free cash flow margin	-106.8%+20.8pp	-127.6%+12.9pp	-140.5%-6.5pp	-134%+29.4pp	-163.4%+58.5pp
Returns
Return on equity	-47.5%+8.0pp	-55.5%-1.6pp	-53.9%-0.7pp	-53.2%-1.3pp	-51.8%+5.6pp
Return on assets	-37.4%+5.5pp	-42.9%-0.9pp	-41.9%-0.3pp	-41.7%-0.8pp	-40.9%+3.1pp
Return on invested capital	-59.5%+5.7pp	-65.2%0.0pp	-65.2%+1.4pp	-66.6%-4.2pp	-62.4%+7.5pp
Efficiency
Asset turnover	0.3×0.0×	0.3×0.0×	0.3×0.0×	0.3×0.0×	0.2×0.0×
Inventory turnover	2.9×-0.6×	3.5×-0.4×	3.9×—	——	——
Liquidity
Current ratio	3.6×+0.4×	3.2×-0.2×	3.4×+0.1×	3.3×-0.9×	4.2×+0.4×
Quick ratio	3.2×+0.3×	2.8×-0.2×	3×+0.1×	2.9×-0.8×	3.6×+0.3×
Cash ratio	1.5×+0.3×	1.2×-0.1×	1.3×+0.2×	1×-0.4×	1.4×+0.5×
Leverage
Debt-to-equity	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Debt-to-assets	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Valuation
Market capitalization	$1.45B+33.4%	$1.08B+38.0%	$785.22M+25.1%	$627.8M-42.5%	$1.09B-51.6%
Enterprise value	$1.3B+33.8%	$969.09M+42.8%	$678.58M+23.9%	$547.49M-43.7%	$972.88M-55.7%
Price / sales	5.1×+1.0×	4.1×+1.0×	3.1×+0.5×	2.6×-2.5×	5.1×-8.6×
Price / book	2×+0.5×	1.6×+0.4×	1.1×+0.2×	0.9×-0.5×	1.4×-1.8×
EV / sales	4.5×+0.9×	3.7×+1.0×	2.7×+0.4×	2.3×-2.3×	4.6×-8.8×
Free cash flow yield	-21.1%+9.9pp	-31%+13.8pp	-44.8%+6.7pp	-51.5%-19.7pp	-31.8%-15.7pp
Earnings yield	-24.5%+11.6pp	-36.1%+14.6pp	-50.6%+11.5pp	-62.1%-27.7pp	-34.4%-17.9pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Iovance Biotherapeutics, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Iovance Biotherapeutics, Inc.'s profit margins?: Iovance Biotherapeutics, Inc. (IOVA) runs a 36.7% gross margin and a -127.2% operating margin, with a -123.9% net margin.
Where do Iovance Biotherapeutics, Inc.'s ratios come from?: Every ratio is computed from Iovance Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.